Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marshall Edwards has started dosing in an open-label, dose-escalation Phase I trial evaluating ME-143 in patients suffering from refractory solid tumors.
Subscribe to our email newsletter
The trial aims to evaluate the the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors.
The Phase I trial expects to recruit around 24 patients.
In pre-clinical studies, ME-143 has demonstrated potent activity against a number of tumor cell lines, including breast, colorectal and ovarian.